ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases

BARCELONA, SPAIN and CAMBRIDGE MA.

• Data allows establishment of a safe administration scheme for long term efficacy studies

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented last Friday preliminary data on the First in Human clinical trial of ORY-2001 at the 13th international Conference on Alzheimer’s and Parkinson’s disease celebrated in Vienna, Austria.

Click here to see the full Press Release